CN113975337A - 一种适于儿童的鼻炎喷剂及其制备方法 - Google Patents
一种适于儿童的鼻炎喷剂及其制备方法 Download PDFInfo
- Publication number
- CN113975337A CN113975337A CN202111054597.4A CN202111054597A CN113975337A CN 113975337 A CN113975337 A CN 113975337A CN 202111054597 A CN202111054597 A CN 202111054597A CN 113975337 A CN113975337 A CN 113975337A
- Authority
- CN
- China
- Prior art keywords
- rhinitis
- chinese medicine
- traditional chinese
- children
- chlorpheniramine maleate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 95
- 239000007921 spray Substances 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 83
- 238000002347 injection Methods 0.000 claims abstract description 60
- 239000007924 injection Substances 0.000 claims abstract description 60
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 59
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims abstract description 58
- BITDLWAQPKSXTF-UHFFFAOYSA-M 1-[(3-nitrophenyl)methoxymethyl]pyridin-1-ium;chloride Chemical compound [Cl-].[O-][N+](=O)C1=CC=CC(COC[N+]=2C=CC=CC=2)=C1 BITDLWAQPKSXTF-UHFFFAOYSA-M 0.000 claims abstract description 56
- 229960002581 moroxydine hydrochloride Drugs 0.000 claims abstract description 56
- 239000000243 solution Substances 0.000 claims abstract description 43
- 239000000284 extract Substances 0.000 claims abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 238000001914 filtration Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000002994 raw material Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 24
- 241000758794 Asarum Species 0.000 claims description 19
- 241000245665 Taraxacum Species 0.000 claims description 18
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- 241000628997 Flos Species 0.000 claims description 14
- 239000009670 cang er zi wan Substances 0.000 claims description 14
- 229950008882 polysorbate Drugs 0.000 claims description 13
- 229920000136 polysorbate Polymers 0.000 claims description 13
- 238000002791 soaking Methods 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- 239000008215 water for injection Substances 0.000 claims description 13
- 241000218671 Ephedra Species 0.000 claims description 11
- 238000001256 steam distillation Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 claims description 6
- 241000218378 Magnolia Species 0.000 claims description 5
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 5
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 208000024891 symptom Diseases 0.000 abstract description 14
- 210000002850 nasal mucosa Anatomy 0.000 abstract description 10
- 241000700605 Viruses Species 0.000 abstract description 9
- 210000004072 lung Anatomy 0.000 abstract description 6
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 5
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 208000014674 injury Diseases 0.000 abstract description 4
- 238000009499 grossing Methods 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 2
- 230000009325 pulmonary function Effects 0.000 abstract description 2
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 206010039101 Rhinorrhoea Diseases 0.000 description 5
- 208000010753 nasal discharge Diseases 0.000 description 5
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 4
- 239000007923 nasal drop Substances 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 3
- 241001506766 Xanthium Species 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 229960005016 naphazoline Drugs 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 244000001632 Acorus gramineus Species 0.000 description 1
- 235000013073 Acorus gramineus Nutrition 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 230000001834 epinephrinelike Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于于鼻炎治疗药剂技术领域,尤其为一种适于儿童的鼻炎喷剂及其制备方法,该适于儿童的鼻炎喷剂由马来酸氯苯那敏注射液、盐酸吗啉胍注射液、中药提取液等各种组分按照一定配比制备成,其中的马来酸氯苯那敏注射液所包含的马来酸氯苯那敏可治疗过敏性鼻炎,能够改善鼻炎本身的症状;盐酸吗啉胍注射液在该喷剂中主要作用是杀菌,对病毒增殖周期各个阶段均有抑制作用;中药提取液有明显的祛风清热、宣肺通窍、保护鼻腔粘膜的效果,主要用于治疗鼻炎引起的湿热、鼻腔粘膜损伤、肺功能下降等次级症状,因此,该适于儿童的鼻炎喷剂具有标本兼治的效果,没有包含对儿童不适的成分,对儿童鼻炎的治疗效果比较显著。
Description
技术领域
本发明属于鼻炎治疗药剂技术领域,具体涉及一种适于儿童的鼻炎喷剂及其制备方法。
背景技术
鼻炎指的是鼻腔粘膜和粘膜下组织的炎症,一般是由于病毒感染、遗传因素、抗原物 质等的刺激引起。其中,病毒感染是鼻炎发生的首要病因,或在病毒感染的基础上继发细 菌感染,已知有100多种病毒可引起鼻炎,最常见的是鼻病毒,其次是流感和副流感病毒、 腺病毒、冠状病毒、柯萨奇病毒及黏液和副黏液病毒等,病毒传播方式主要是经过呼吸道 吸入,其次是通过被污染体或食物进入机体。
鼻炎的症状通常表现为充血或水肿,患者经常会出现鼻塞、流清水涕、鼻痒、喉部不 适、咳嗽等症状,通常情况下,鼻腔分泌物可帮助清除灰尘、细菌以保持肺部的健康,当鼻内出现炎症时,鼻腔内可以分泌大量的鼻涕,并可以因感染而变成黄色,流经咽喉时可以引起咳嗽,鼻涕量十分多时还可以经前鼻孔流出,从而产生鼻炎症状。
目前市售的有喷剂、片剂等各种主要适于成人的鼻炎药,对于儿童来说,使用起来并 不合适,比如,一种滴鼻液的主要成分是萘唑啉,对鼻炎治疗效果较好,但是,萘唑啉成分是一种拟肾上腺素药,这种药品会导致儿童出现嗜睡、呕吐等症状,该药是禁用于儿童患者的,目前国内已有多起儿童用该药引起中毒的报道。
现有技术中,申请人此前发明了一种滴鼻液及其制备方法(见公开号为CN106668094A 的中国专利文献),通过马来酸氯苯那敏、盐酸吗啉胍、柴胡等相关药液配比后制备成, 该滴鼻液具有配方安全、毒副作用小、中药和西药搭配合理、适合儿童使用的优势,但是 该滴鼻液主要是用于消除鼻炎本身症状,对于鼻炎引起的湿热、鼻腔粘膜损伤、肺功能下 降等次级症状没有明显的改善,整体治疗效果相对单一,为此,发明人在后续诊疗、研发 过程中对该滴鼻液继续改进和验证,发明了一种效果更优的鼻炎治疗药物。
发明内容
本发明旨在提供一种适于儿童的鼻炎喷剂及其制备方法,解决现有技术中鼻炎治疗药 物疗效单一的技术问题。
为解决上述技术问题,本发明的第一方面是:
提供一种适于儿童的鼻炎喷剂,由以下重量配比的原料药制成:
由柴胡、白芷、辛夷、石菖蒲、苍耳子、麻黄、黄芩、细辛、蒲公英制取的中药提取 液3~6mL;
马来酸氯苯那敏注射液1~2mL,含有马来酸氯苯那敏10~20mg;
盐酸吗啉胍注射液1~3mL,含有盐酸吗啉胍50~150mg。
优选的,所述中药提取液的制备方法如下:取柴胡800~1200g、白芷400~600g、辛夷400~600g、石菖蒲300~500g、苍耳子300~500g、麻黄30~70g、黄芩80~120g、细 辛80~120g、蒲公英200~400g,分别切成0.5-2mm片段,加水浸泡,经水蒸气蒸馏,收 集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 2~4g,搅拌使液体完全溶解,接 着加入7~11g氯化钠,完全溶解后,滤过,加注射用水定容至3000~3500mL,调节pH值 至7.1~7.3,过滤,即可。
优选的,该适于儿童的鼻炎喷剂由以下重量配比的原料药制成:
马来酸氯苯那敏注射液1~1.5mL,含有马来酸氯苯那敏10~15mg;
盐酸吗啉胍注射液2~3mL,含有盐酸吗啉胍100~150mg;
所述中药提取液3.5~5mL。
优选的,该适于儿童的鼻炎喷剂由以下重量配比的原料药制成:
马来酸氯苯那敏注射液1mL,含有马来酸氯苯那敏10mg;
盐酸吗啉胍注射液2mL,含有盐酸吗啉胍100mg;
所述中药提取液4mL。
优选的,所述中药提取液的制备过程中:取柴胡1000g、白芷500g、辛夷500g、石菖蒲400g、苍耳子400g、麻黄50g、黄芩100g、细辛100g、蒲公英300g,分别切成1mm片 段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 3g, 搅拌使液体完全溶解,接着加入9g氯化钠,完全溶解后,滤过,加注射用水定容至3350mL, 调节pH值至7.1~7.3,过滤,即可。
优选的,所述中药提取液的制备方法如下:所述中药提取液的制备过程中:取柴胡800g、 白芷400g、辛夷400g、石菖蒲300g、苍耳子300g、麻黄30g、黄芩80g、细辛80g、蒲公 英200g,分别切成0.5mm片段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集 重馏液,加入聚山梨酯80 2g,搅拌使液体完全溶解,接着加入7g氯化钠,完全溶解后, 滤过,加注射用水定容至3000mL,调节pH值至7.1~7.3,过滤,即可。
优选的,所述中药提取液的制备方法如下:取柴胡1200g、白芷600g、辛夷600g、石菖蒲500g、苍耳子500g、麻黄70g、黄芩120g、细辛120g、蒲公英400g,分别切成2mm 片段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 4g,搅拌使液体完全溶解,接着加入11g氯化钠,完全溶解后,滤过,加注射用水定容至 3500mL,调节pH值至7.1~7.3,过滤,即可。
本发明的第二方面是:
提供一种适于儿童的鼻炎喷剂的制备方法,包括:
(1)准备马来酸氯苯那敏注射液1~2mL,含有马来酸氯苯那敏10~20mg;准备盐酸吗啉胍注射液1~3mL,含有盐酸吗啉胍50~150mg;
(2)准备中药提取液3~6mL,所述中药提取液由柴胡、白芷、辛夷、石菖蒲、苍耳子、麻黄、黄芩、细辛、蒲公英制取,所述中药提取液的制备方法如下:取柴胡800~1200g、白芷400~600g、辛夷400~600g、石菖蒲300~500g、苍耳子300~500g、麻黄30~70g、 黄芩80~120g、细辛80~120g、蒲公英200~400g,分别切成0.5-2mm片段,加水浸泡, 经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 2~4g,搅拌使 液体完全溶解,接着加入7~11g氯化钠,完全溶解后,滤过,加注射用水定容至3000~ 3500mL,调节pH值至7.1~7.3,过滤,即可;
(4)将上述各个原料药物按照上述比例混合,配置而成后装入容器中。
与现有技术相比,本发明的有益效果是:该适于儿童的鼻炎喷剂由马来酸氯苯那敏注 射液、盐酸吗啉胍注射液、中药提取液等各种组分按照一定配比制备成,其中的马来酸氯 苯那敏注射液所包含的马来酸氯苯那敏可治疗过敏性鼻炎,对过敏性鼻炎和上呼吸道感染 引起的鼻充血有效,能够改善鼻炎本身的症状;盐酸吗啉胍注射液在该喷剂中主要作用是 杀菌,对病毒增殖周期各个阶段均有抑制作用;中药提取液有明显的祛风清热、宣肺通窍、 保护鼻腔粘膜的效果,主要用于治疗鼻炎引起的湿热、鼻腔粘膜损伤、肺功能下降等次级 症状。因此,该适于儿童的鼻炎喷剂具有标本兼治的效果,没有包含对儿童不适的成分, 对儿童鼻炎的治疗效果比较显著,并且不使用激素,不会产生依赖性,特别适于儿童使用。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
一种适于儿童的鼻炎喷剂,该适于儿童的鼻炎喷剂是由如下重量配比的原料药物配制 而成:
马来酸氯苯那敏注射液1~2mL,含有马来酸氯苯那敏10~20mg;
盐酸吗啉胍注射液1~3mL,含有盐酸吗啉胍50~150mg;
中药提取液3~6mL,该中药提取液由柴胡、白芷、辛夷、石菖蒲、苍耳子、麻黄、黄芩、细辛、蒲公英制取。该中药提取液的制备方法为:取柴胡1000g、白芷500g、辛夷500g、 石菖蒲400g、苍耳子400g、麻黄50g、黄芩100g、细辛100g、蒲公英300g,切成0.5-2mm 片段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 3g,搅拌使油完全溶解,接着加入9g氯化钠,完全溶解后,滤过,加注射用水定容至3350mL, 调节pH值至7.1~7.3,过滤,即可。
该儿童的鼻炎喷剂的制备方法如下:准备上述重量配比的马来酸氯苯那敏注射液、盐 酸吗啉胍注射液、中药提取液,将准备的各个原料药物按照上述比例混合,配置而成后装 入容器中。
实施例2:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1mL,含有马来酸氯苯那敏10mg;
盐酸吗啉胍注射液2mL,含有盐酸吗啉胍100mg;
中药提取液4mL。
其中,本实施例中的中药提取液的制备方法如下:取柴胡800g、白芷400g、辛夷400g、 石菖蒲300g、苍耳子300g、麻黄30g、黄芩80g、细辛80g、蒲公英200g,分别切成0.5mm片段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 2g,搅拌使液体完全溶解,接着加入7g氯化钠,完全溶解后,滤过,加注射用水定容至 3000mL,调节pH值至7.1~7.3,过滤,即可。
本实施例适于儿童的鼻炎喷剂的制备方法与实施例1相同。
实施例3:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1mL,含有马来酸氯苯那敏10mg;
盐酸吗啉胍注射液3mL,含有盐酸吗啉胍150mg;
中药提取液6mL。
其中,本实施例中的中药提取液的制备方法如下:取柴胡1200g、白芷600g、辛夷600g、 石菖蒲500g、苍耳子500g、麻黄70g、黄芩120g、细辛120g、蒲公英400g,分别切成2mm片段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 4g,搅拌使液体完全溶解,接着加入11g氯化钠,完全溶解后,滤过,加注射用水定容至 3500mL,调节pH值至7.1~7.3,过滤,即可。
本实施例适于儿童的鼻炎喷剂的制备方法与实施例1相同。
实施例4:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1.2mL,含有马来酸氯苯那敏12mg;
盐酸吗啉胍注射液2.5mL,含有盐酸吗啉胍125mg;
中药提取液5.5mL。
本实施例其余部分与实施例1相同。
实施例5:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1.4mL,含有马来酸氯苯那敏14mg;
盐酸吗啉胍注射液2mL,含有盐酸吗啉胍100mg;
中药提取液5mL。
本实施例其余部分与实施例1相同。
实施例6:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1.5mL,含有马来酸氯苯那敏15mg;
盐酸吗啉胍注射液1.5mL,含有盐酸吗啉胍75mg;
中药提取液4.5mL。
本实施例其余部分与实施例1相同。
实施例7:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1.6mL,含有马来酸氯苯那敏16mg;
盐酸吗啉胍注射液1.4mL,含有盐酸吗啉胍70mg;
中药提取液4mL。
本实施例其余部分与实施例1相同。
实施例8:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1.7mL,含有马来酸氯苯那敏17mg;
盐酸吗啉胍注射液1.2mL,含有盐酸吗啉胍60mg;
中药提取液3.5mL。
本实施例其余部分与实施例1相同。
实施例9:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1.8mL,含有马来酸氯苯那敏18mg;
盐酸吗啉胍注射液1mL,含有盐酸吗啉胍50mg;
中药提取液3mL。
本实施例其余部分与实施例1相同。
实施例10:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1.5mL,含有马来酸氯苯那敏15mg;
盐酸吗啉胍注射液3mL,含有盐酸吗啉胍150mg;
中药提取液3.5mL。
本实施例其余部分与实施例1相同。
实施例11:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液2mL,含有马来酸氯苯那敏20mg;
盐酸吗啉胍注射液1.5mL,含有盐酸吗啉胍100mg;
中药提取液3mL。
本实施例其余部分与实施例1相同。
实施例12:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1mL,含有马来酸氯苯那敏10mg;
盐酸吗啉胍注射液1mL,含有盐酸吗啉胍50mg;
中药提取液5mL。
本实施例其余部分与实施例1相同。
实施例13:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1.5mL,含有马来酸氯苯那敏15mg;
盐酸吗啉胍注射液2mL,含有盐酸吗啉胍100mg;
中药提取液4mL。
本实施例其余部分与实施例1相同。
实施例14:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液2mL,含有马来酸氯苯那敏20mg;
盐酸吗啉胍注射液1mL,含有盐酸吗啉胍50mg;
中药提取液4.5mL。
本实施例其余部分与实施例1相同。
实施例15:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液1.8mL,含有马来酸氯苯那敏18mg;
盐酸吗啉胍注射液3mL,含有盐酸吗啉胍150mg;
中药提取液6mL。
本实施例其余部分与实施例1相同。
实施例16:
一种适于儿童的鼻炎喷剂,与实施例1的不同之处在于,本实施例适于儿童的鼻炎喷 剂是由如下重量配比的原料药物配制而成:
马来酸氯苯那敏注射液2mL,含有马来酸氯苯那敏20mg;
盐酸吗啉胍注射液3mL,含有盐酸吗啉胍150mg;
中药提取液3.5mL。
本实施例其余部分与实施例1相同。
前述实施例中适于儿童的鼻炎喷剂的使用方法为:将该适于儿童的鼻炎喷剂装入喷雾 瓶里,在日间,每间隔三个小时对两个鼻腔各喷一次,直到鼻炎症状消失。
本发明适于儿童的鼻炎喷剂各组分的药理说明:
(1)中药提取液:该中药提取液中的柴胡有明显的退热作用,白芷具有消肿止痛的作用,辛夷具有发散风寒、通鼻窍的作用,石菖蒲具有平喘、镇静、抗菌的作用,苍耳子 具有发散风寒、通鼻窍的作用,麻黄具有发汗宣肺、消肿的作用,黄芩具有清热泻火的作 用,细辛具有驱寒、温肺的作用,蒲公英具有清热解毒的作用。
(2)马来酸氯苯那敏注射液:所包含的马来酸氯苯那敏可治疗过敏性鼻炎,对过敏性鼻炎和上呼吸道感染引起的鼻充血有效,可用于感冒或鼻窦炎、皮肤粘膜的过敏,对荨麻疹、枯草热、血管运动性鼻炎均有效,并能缓解虫咬所致皮肤瘙痒和水肿,也可用于控 制药疹和接触性皮炎。
(3)盐酸吗啉胍注射液:
能抑制病毒的DNA和RNA聚合酶,从而抑制病毒繁殖,在人胚肾细胞上1%浓度对DNA 病毒(腺病毒疱疹病毒)和RNA病毒(埃可病毒)都有明显抑制作用,对病毒增殖周期各个阶段均有抑制作用。
马来酸氯苯那敏是起到抗过敏,保护鼻腔黏膜的作用,盐酸吗啉胍是起到抗病毒,保 护鼻腔黏膜的作用;中药提取液有明显的祛风清热、宣肺通窍、保护鼻腔粘膜的效果,主要用于治疗鼻炎引起的湿热、鼻腔粘膜损伤、肺功能下降等次级症状。
病例治疗效果统计:
如下表所示,发明人从2017年10月至2021年7月年共统计收治患有鼻炎幼儿患者101例,病程为10天至20天不等,共治愈95例,占94.05%,症状明显好转1例,约占 0.99%,症状好转4人,约占3.9%,总体治疗效果良好。
表1-病例治疗情况统计表
需要说明的是,在本文中,诸如术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者 设备所固有的要素。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解, 在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变 型,本发明的范围由所附权利要求及其等同物限定。
Claims (8)
1.一种适于儿童的鼻炎喷剂,其特征在于,由以下重量配比的原料药制成:
由柴胡、白芷、辛夷、石菖蒲、苍耳子、麻黄、黄芩、细辛、蒲公英制取的中药提取液3~6mL;
马来酸氯苯那敏注射液1~2mL,含有马来酸氯苯那敏10~20mg;
盐酸吗啉胍注射液1~3mL,含有盐酸吗啉胍50~150mg。
2.根据权利要求1所述的适于儿童的鼻炎喷剂,其特征在于,所述中药提取液的制备方法如下:取柴胡800~1200g、白芷400~600g、辛夷400~600g、石菖蒲300~500g、苍耳子300~500g、麻黄30~70g、黄芩80~120g、细辛80~120g、蒲公英200~400g,分别切成0.5-2mm片段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 2~4g,搅拌使液体完全溶解,接着加入7~11g氯化钠,完全溶解后,滤过,加注射用水定容至3000~3500mL,调节pH值至7.1~7.3,过滤,即可。
3.根据权利要求1所述的适于儿童的鼻炎喷剂,其特征在于,由以下重量配比的原料药制成:
马来酸氯苯那敏注射液1~1.5mL,含有马来酸氯苯那敏10~15mg;
盐酸吗啉胍注射液2~3mL,含有盐酸吗啉胍100~150mg;
所述中药提取液3.5~5mL。
4.根据权利要求1所述的适于儿童的鼻炎喷剂,其特征在于,由以下重量配比的原料药制成:
马来酸氯苯那敏注射液1mL,含有马来酸氯苯那敏10mg;
盐酸吗啉胍注射液2mL,含有盐酸吗啉胍100mg;
所述中药提取液4mL。
5.根据权利要求2所述的适于儿童的鼻炎喷剂,其特征在于,所述中药提取液的制备过程中:取柴胡1000g、白芷500g、辛夷500g、石菖蒲400g、苍耳子400g、麻黄50g、黄芩100g、细辛100g、蒲公英300g,分别切成1mm片段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 3g,搅拌使液体完全溶解,接着加入9g氯化钠,完全溶解后,滤过,加注射用水定容至3350mL,调节pH值至7.1~7.3,过滤,即可。
6.根据权利要求2所述的适于儿童的鼻炎喷剂,其特征在于,所述中药提取液的制备方法如下:所述中药提取液的制备过程中:取柴胡800g、白芷400g、辛夷400g、石菖蒲300g、苍耳子300g、麻黄30g、黄芩80g、细辛80g、蒲公英200g,分别切成0.5mm片段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 2g,搅拌使液体完全溶解,接着加入7g氯化钠,完全溶解后,滤过,加注射用水定容至3000mL,调节pH值至7.1~7.3,过滤,即可。
7.根据权利要求2所述的适于儿童的鼻炎喷剂,其特征在于,所述中药提取液的制备方法如下:取柴胡1200g、白芷600g、辛夷600g、石菖蒲500g、苍耳子500g、麻黄70g、黄芩120g、细辛120g、蒲公英400g,分别切成2mm片段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 4g,搅拌使液体完全溶解,接着加入11g氯化钠,完全溶解后,滤过,加注射用水定容至3500mL,调节pH值至7.1~7.3,过滤,即可。
8.一种适于儿童的鼻炎喷剂的制备方法,其特征在于,包括:
(1)准备马来酸氯苯那敏注射液1~2mL,含有马来酸氯苯那敏10~20mg;准备盐酸吗啉胍注射液1~3mL,含有盐酸吗啉胍50~150mg;
(2)准备中药提取液3~6mL,所述中药提取液由柴胡、白芷、辛夷、石菖蒲、苍耳子、麻黄、黄芩、细辛、蒲公英制取,所述中药提取液的制备方法如下:取柴胡800~1200g、白芷400~600g、辛夷400~600g、石菖蒲300~500g、苍耳子300~500g、麻黄30~70g、黄芩80~120g、细辛80~120g、蒲公英200~400g,分别切成0.5-2mm片段,加水浸泡,经水蒸气蒸馏,收集初馏液,再重蒸馏,收集重馏液,加入聚山梨酯80 2~4g,搅拌使液体完全溶解,接着加入7~11g氯化钠,完全溶解后,滤过,加注射用水定容至3000~3500mL,调节pH值至7.1~7.3,过滤,即可;
(4)将上述各个原料药物按照上述比例混合,配置而成后装入容器中。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111054597.4A CN113975337A (zh) | 2021-09-09 | 2021-09-09 | 一种适于儿童的鼻炎喷剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111054597.4A CN113975337A (zh) | 2021-09-09 | 2021-09-09 | 一种适于儿童的鼻炎喷剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113975337A true CN113975337A (zh) | 2022-01-28 |
Family
ID=79735490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111054597.4A Pending CN113975337A (zh) | 2021-09-09 | 2021-09-09 | 一种适于儿童的鼻炎喷剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113975337A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2784279C1 (ru) * | 2022-05-05 | 2022-11-23 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Тюменский Государственный Медицинский Университет" Министерства Здравоохранения Российской Федерации | Способ профилактики и лечения аллергического ринита до и после эндоскопической аденотомии у детей |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104398711A (zh) * | 2014-12-05 | 2015-03-11 | 南京中医药大学 | 一种治疗儿童过敏性鼻炎的中药组合物及其制备方法和应用 |
CN106668094A (zh) * | 2017-03-23 | 2017-05-17 | 栗明峰 | 一种滴鼻液及其制备方法 |
CN106860622A (zh) * | 2016-08-31 | 2017-06-20 | 肇庆星湖制药有限公司 | 一种用于治疗各种鼻炎的中药复方制剂及其制备方法和应用 |
CN109674910A (zh) * | 2019-02-21 | 2019-04-26 | 天津中医药大学 | 一种治疗鼻炎药物及其制备方法 |
-
2021
- 2021-09-09 CN CN202111054597.4A patent/CN113975337A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104398711A (zh) * | 2014-12-05 | 2015-03-11 | 南京中医药大学 | 一种治疗儿童过敏性鼻炎的中药组合物及其制备方法和应用 |
CN106860622A (zh) * | 2016-08-31 | 2017-06-20 | 肇庆星湖制药有限公司 | 一种用于治疗各种鼻炎的中药复方制剂及其制备方法和应用 |
CN106668094A (zh) * | 2017-03-23 | 2017-05-17 | 栗明峰 | 一种滴鼻液及其制备方法 |
CN109674910A (zh) * | 2019-02-21 | 2019-04-26 | 天津中医药大学 | 一种治疗鼻炎药物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
左言富等: "《简明中成药辞典》", 31 October 2002 * |
彭成等: "《中国临床药物大辞典 中药成方制剂卷 上》", 31 August 2008 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2784279C1 (ru) * | 2022-05-05 | 2022-11-23 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Тюменский Государственный Медицинский Университет" Министерства Здравоохранения Российской Федерации | Способ профилактики и лечения аллергического ринита до и после эндоскопической аденотомии у детей |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023512529A (ja) | 清肺排毒機能を有する漢方薬複合処方及びその応用 | |
CN102813702A (zh) | 鼻炎药水 | |
CN101972418A (zh) | 一种预防和治疗感冒的保健茶 | |
CN116139237B (zh) | 一种防治新型冠状病毒等所致呼吸道感染的中药组合物及其应用 | |
CN102274322A (zh) | 一种治疗湿疹的中药制剂 | |
CN102274405A (zh) | 一种治疗脑震荡后遗症的药物 | |
CN113975337A (zh) | 一种适于儿童的鼻炎喷剂及其制备方法 | |
CN101987156B (zh) | 一种治疗牙痛的药物及其制备方法 | |
CN104352880A (zh) | 用于治疗狗细菌感染性感冒的药物组合物及其制备方法 | |
CN113332377B (zh) | 一种用于病毒性肺炎治疗的中药复方制剂 | |
CN101129755A (zh) | 一种内服治疗哮喘的中药组合物 | |
CN1058164C (zh) | 一种治疗跌打损伤的酊剂 | |
CN106074906A (zh) | 一种治疗感冒的中药组合物 | |
CN115300544B (zh) | 一种疏风解表、消肿通窍的中药组合物、贴剂及制备方法 | |
CN105106895A (zh) | 一种治疗肾炎的复方中药口服液及其制备工艺 | |
CN114042109B (zh) | 一种通窍止涕、温阳固本的中药组合物、贴剂及制备方法 | |
CN105079333A (zh) | 一种治疗尿路结石的药物 | |
CN101904962B (zh) | 一种治疗感冒的药物及其制备方法 | |
CN108066406A (zh) | 一种治疗小儿急性扁桃体炎病症的中药 | |
CN101259165A (zh) | 柴黄制剂及其生产方法 | |
CN106389744A (zh) | 一种治疗痛风的中医药物配方 | |
CN105194634A (zh) | 一种用于小儿退热的中药组合物及其制备方法 | |
CN105213678A (zh) | 一种清肺、止咳、化痰的中药组合物 | |
CN105853760A (zh) | 一种骨科膏药及其制备方法 | |
CN105288326A (zh) | 一种治疗失眠的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220128 |